Limbo
5 known investors
Limbo is a health tech startup using continuous glucose monitors and connected wearables in a subscription weight-management program.
Also known as Limbo Revolution
Investors · 5
Also in the syndicate · 3
Company profile
researched Aug 2026Limbo is a health technology startup building a subscription weight-management service around continuous glucose monitoring (CGM). Members are supplied with CGM sensors that transmit near real-time blood glucose data to a companion app, plus two additional connected devices: a wearable wristband tracking heart rate, steps, skin and body temperature and blood oxygen, and a smart scale that measures body fat and muscle mass across different areas of the body. The combined signals are used to assess diet and lifestyle and to track progress toward weight goals.
The program is based on roughly three decades of private research by co-founder and chief research officer Tony Martin, a physiologist and coach, who studied how blood glucose regulates energy in the body and, over the five to six years preceding 2022, used CGMs to test hypotheses on himself and his weight-loss clients. The resulting method is described as a ketogenic-type approach balancing macronutrients, with carbohydrate and sugar reduction individualized per member and steered in real time by CGM readings. Martin is not affiliated with a research institution and has not published scientific papers on the work.
Founding story
The company traces its origin to co-founder Pat Phelan's own obesity and weight-loss experience following years of startup travel. Phelan, who previously exited ecommerce fraud protection startup Trustev to TransUnion for $44 million in 2015, met physiologist and coach Tony Martin, who suggested Phelan try his blood glucose tracking method with a CGM. Phelan reported losing 36 kg (81 pounds) over nine months on the prototype program, and he, Martin and Rurik Bradbury came together to productize Martin's method as a company, with Phelan and Bradbury contributing startup and technology experience.
Business model
Subscription service in which members pay for access to a coached, data-driven weight-management program and receive the accompanying hardware, including CGM sensors, a wristband wearable and a smart scale.
Subscription pricing of £1,500 for three months of access to the program, described as premium-level pricing.
Traction
As of September 2022 the company reported around 2,000 members, up from an initial paying cohort of 50. It cited average weight loss of 12% after three months of use among that initial cohort. No efficacy studies comparing the method to other weight-management approaches had been published.
Latest developments
In September 2022 Limbo announced a $6 million seed round led by Hoxton Ventures, with participation from Rory Sexton, Jamie Heaslip and Shaquille O'Neal. Sexton, a former Apple executive in Asia and one of the first investors, sits on the company's board.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Limbo operates among a group of startups commercializing continuous glucose monitoring technology beyond its original diabetes-management use, in areas such as metabolic tracking, athletic performance and weight management.
Limbo positions its offering as a structured program derived from a defined physiological methodology rather than a data-collection product still searching for a use case, with CGM data used to steer individualized macronutrient balance in real time and hardware customized for higher data resolution than mainstream consumer wearables.
Technology
The product combines continuous glucose monitors — semi-invasive sensors typically worn on the arm with a filament inserted under the skin — with a companion mobile app and two connected devices. The wristband began as an off-the-shelf device and was subsequently customized to the company's specifications, in part because of the low data resolution of consumer devices such as Apple Watch and Fitbit; an Apple Watch integration was also built. The smart scale measures body fat and muscle mass by body area. Company representatives noted power-consumption and accuracy constraints as obstacles to non-invasive blood glucose sensing in consumer smartwatches.
Go-to-market
Adults seeking to lose approximately 10-15% of their body weight; typical customers as of 2022 were in the 35-55 age range.
Geography
Operations described across New York, London and Cork.
History
Limbo was founded in the fall of 2020, with the first private beta users starting on the program at the end of 2020. An initial paying cohort numbered 50 users. In September 2022 the company announced a $6 million seed round and said it had grown to around 2,000 members, with a stated goal of tens of thousands of sign-ups over the following 12 months.
Risks & controversies
The underlying methodology is private research: chief research officer Tony Martin holds no research-institution affiliation and has not published scientific papers, and the company had no published efficacy studies quantifying the program's impact relative to other weight-management approaches as of September 2022. Reported outcome figures derive from a small initial cohort of 50 paying users.
Compiled by commissioned research from 7 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsLimbo announced a $6 million seed raise led by Hoxton Ventures, with investors including Rory Sexton, Jamie Heaslip and Shaquille O'Neal, to build a CGM-based subscription weight management business.
$6M source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 7
primary sources listed
- Limbo raised $6 million in a round led by Hoxton Ventures.nordic9.com · web
7 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Limbo do?
- Limbo is a health tech startup using continuous glucose monitors and connected wearables in a subscription weight-management program.
- Who are Limbo's investors?
- Limbo's investors include Hoxton Ventures, Seedcamp.